Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NuPathe licenses drug delivery technology
The company is currently applying the long-acting delivery (LAD) technology to investigational drug candidates for the treatment of Parkinson’s disease and schizophrenia. The LAD technology is designed to
The company is currently applying the long-acting delivery (LAD) technology to investigational drug candidates for the treatment of Parkinson’s disease and schizophrenia. The LAD technology is designed to
The active ingredient contained within Bema LA met the company’s expectations in terms of the amount absorbed into the bloodstream. Plasma concentrations (amount of active ingredient in the
The recommendation came following a meeting of the independent data safety monitoring board (DSMB). This was the fifth of several regularly scheduled reviews by the DSMB that will
The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ALS 2-0426. Designed in two parts, the initial double-blind, placebo controlled phase I clinical study will enroll
The data, which were presented at the recent Internationals AIDS Conference, were the final 48 week analysis of a phase IIb dose-finding study in HIV-1 infected adult patients
Abbott acquired the product through the acquisition of Knoll AG in 2002 before out-licensing it to Speedel in 2003. Based on the promising results from the phase II
Evotec has granted Takeda exclusive rights to a novel target in Alzheimer’s disease based on successful target identification and validation work triggering a milestone payment of over one
As part of the reorganization, David Shedlarz, vice chairman, will become principle deputy to Mr Kindler with expanded responsibilities including Pfizer global manufacturing, and worldwide strategic planning, licensing
The studies, which have been published in the Journal of Immunology, advance the understanding of rheumatoid arthritis (RA) and demonstrate that inhibiting a molecule named TWEAK may provide
HIV-1-infected subjects treated with the proprietary retrovirus-based vector showed long-term presence of the engineered CD34+ stem cells as well as a long-term presence of engineered CD4+ immune cells